"SURUNKALI BUYRAK KASALLIGIDA OSTEOPOROZ RIVOJLANISHINING KLINIK-DIAGNOSTIK JIHATLARI"
Keywords:
Kalit so'zlar: surunkali buyrak kasalligi, osteoporoz, mineral suyak kasalligi, sekonder giperparatiroidizm, D vitamini, suyak mineral zichligi, biokimyoviy markerlar, bisosfonatlar, kaltsimimetiklar.Abstract
ANNOTATSIYA
Surunkali buyrak kasalligi (SBK) nafaqat nefronlarning progressiv yo'qolishi va
glomerulyar filtratsiya tezligining (GFT) pasayishi bilan tavsiflanadi, balki mineral va
suyak metabolizmining murakkab patologik buzilishlariga ham olib keladigan tizimli
kasallikdir. Mineral suyak kasalligi (MSK) SBK ning asosiy ekstrarenal asoratlaridan
biri bo'lib, osteoporoz, osteomalatsiya, suyak kasalligi va giperparatiroidizm kabi
holatlarni o'z ichiga oladi. Osteoporoz - suyak massasining pasayishi va
mikroarxitekturasining buzilishi natijasida patologik sinishlar xavfining sezilarli
darajada oshishiga olib keladigan sistemali metabolik kasallik hisoblanadi.
References
ADABIYOTLAR RO'YXATI
1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group.
KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation,
Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder
(CKD-MBD). Kidney Int Suppl. 2017;7(1):1-59.
2. National Kidney Foundation. K/DOQI clinical practice guidelines for bone
metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4
Suppl 3):S1-201.
3. Moe SM, Drüeke TB, Block GA, et al. Kidney Disease: Improving Global
Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline
for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney
Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. 2009;76(Suppl
113):S1-130.
4. Gal-Moscovici A, Sprague SM. Osteoporosis and chronic kidney disease-mineral
and bone disorder. Osteoporos Int. 2013;24(3):865-873.
5. Miller PD. Diagnosis and treatment of osteoporosis in chronic renal disease. Semin
Nephrol. 2009;29(2):144-155.
6. Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism:
pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol.
2011;6(4):913-921.
7. Ketteler M, Elder GJ, Evenepoel P, et al. Revisiting KDIGO clinical practice
guideline on chronic kidney disease-mineral and bone disorder: a commentary
from a Kidney Disease: Improving Global Outcomes controversies conference.
Kidney Int. 2015;87(3):502-528.
8. Evenepoel P, Bover J, Ureña Torres P. Parathyroid hormone metabolism and
signaling in health and chronic kidney disease. Kidney Int. 2016;90(6):1184-1190.
9. Cozzolino M, Mangano M, Stucchi A, et al. Cardiovascular disease in dialysis
patients. Nephrol Dial Transplant. 2018;33(suppl_3):iii28-iii34.
10. Covic A, Vervloet M, Massy ZA, et al. Bone and mineral disorders in chronic
kidney disease: implications for cardiovascular health and ageing in the general
population. Lancet Diabetes Endocrinol. 2018;6(4):319-331.
